Edition:
India

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
2:29am IST
Change (% chg)

$-0.02 (-1.02%)
Prev Close
$1.96
Open
$1.97
Day's High
$2.01
Day's Low
$1.94
Volume
124,466
Avg. Vol
53,430
52-wk High
$3.69
52-wk Low
$1.66

Latest Key Developments (Source: Significant Developments)

‍Stonepine Capital Management reports 6.6 pct passive stake in Vical
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Vical Inc :‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​.  Full Article

Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Vical Inc :Vical Incorporated announces pricing of $25 million underwritten public offering of common stock.Says public offering of 14.3 million common shares priced at $1.75per share.  Full Article

VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Vical Inc ::VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION.‍INITIAL STAGE OF PROGRAM WILL BE TO DEMONSTRATE PRECLINICAL PROOF OF CONCEPT FOR INHIBITING HBV INFECTION IN HUMAN LIVER MODEL IN H2 2018​.‍ANGES HAS PROVIDED PARTIAL FUNDING FOR INITIAL STAGE OF PROGRAM​.‍IF INITIAL STAGE OF PROGRAM IS SUCCESSFUL, VICAL EXPECTS THAT ANGES WILL CONTINUE TO PARTICIPATE IN FUNDING OF PROGRAM ​.‍ANGES GRANTED RIGHT OF FIRST REFUSAL TO NEGOTIATE WITH CO FOR EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE HEPATITIS B THERAPY IN JAPAN​.  Full Article

Vical reports Q3 loss per share $0.27
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Vical Inc :Vical reports third quarter 2017 financial and operational results.Q3 loss per share $0.27.Q3 revenue $3.2 million versus $2.6 million.  Full Article

Vical Inc files for common stock offering of up to $23.0 mln
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Vical Inc :Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​.  Full Article

Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Vical Inc :Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial.Vical Inc - ‍Astellas Pharma Inc. expects top-line data to be available in Q1 of 2018​.Vical Inc - continues to provide Astellas with development, regulatory and manufacturing support for program​.  Full Article

Vical Q2 loss per share $0.14
Tuesday, 9 Aug 2016 

Vical Inc : Q2 loss per share $0.14 . Vical reports second quarter 2016 financial results . Q2 revenue $4.1 million versus $4.2 million .Projecting net cash burn for 2016 between $8 million and $11 million.  Full Article

Vical announces $7.8 mln equity investment by partner Anges MG
Monday, 1 Aug 2016 

Vical Inc : Vical announces $7.8 million equity investment by partner, Anges MG . Shares are being sold at a price of $4.24 per share .With new investment, Anges' equity position in Vical will increase from 2.4% to approximately 18.6% of Vical's outstanding shares.  Full Article

Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months
Monday, 20 Jun 2016 

Vical Inc : Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline . Vaccine achieved statistically significant reduction in prospectively defined secondary endpoint of genital lesion rate at 3 months versus baseline . Plan to initiate a phase 2 trial of bivalent vaccine during second half of 2016 . Maintain our guidance for net cash burn of between $8 million and $11 million during 2016 .Vical's phase 1/2 trial data presented at asm 2016 shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months.  Full Article

Vical Inc says FDA Grants Vical Orphan Drug Designation for VL-2397
Wednesday, 6 Jan 2016 

Vical Inc:Says FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis.Plan to initiate a Phase 1 clinical trial in the first half of 2016.  Full Article

BRIEF-‍Stonepine Capital Management reports 6.6 pct passive stake in Vical

* ‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​ Source text: (http://bit.ly/2z2Y7Nh) Further company coverage: